Canaan Partners XI LLC Has $28.73 Million Stock Position in Tyra Biosciences, Inc. $TYRA

Canaan Partners XI LLC trimmed its position in shares of Tyra Biosciences, Inc. (NASDAQ:TYRA) by 77.8% during the first quarter, Holdings Channel.com reports. The institutional investor owned 750,000 shares of the company’s stock after selling 2,624,329 shares during the period. Tyra Biosciences accounts for 37.8% of Canaan Partners XI LLC’s investment portfolio, making the stock its 2nd largest holding. Canaan Partners XI LLC’s holdings in Tyra Biosciences were worth $28,725,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in TYRA. Commodore Capital LP increased its stake in shares of Tyra Biosciences by 8.9% during the 3rd quarter. Commodore Capital LP now owns 3,375,000 shares of the company’s stock worth $47,216,000 after purchasing an additional 275,000 shares during the last quarter. Janus Henderson Group PLC boosted its stake in shares of Tyra Biosciences by 2.1% during the 4th quarter. Janus Henderson Group PLC now owns 2,935,442 shares of the company’s stock worth $77,085,000 after acquiring an additional 60,638 shares during the period. Farallon Capital Management LLC raised its stake in Tyra Biosciences by 80.7% in the 4th quarter. Farallon Capital Management LLC now owns 2,066,818 shares of the company’s stock valued at $54,337,000 after acquiring an additional 923,000 shares during the period. Vanguard Group Inc. boosted its position in Tyra Biosciences by 8.5% during the third quarter. Vanguard Group Inc. now owns 1,520,185 shares of the company’s stock worth $21,267,000 after purchasing an additional 118,492 shares during the period. Finally, 5AM Venture Management LLC boosted its position in Tyra Biosciences by 9.6% during the fourth quarter. 5AM Venture Management LLC now owns 1,029,298 shares of the company’s stock worth $27,060,000 after purchasing an additional 90,000 shares during the period. 84.14% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on TYRA shares. Guggenheim initiated coverage on shares of Tyra Biosciences in a research report on Tuesday, April 14th. They issued a “buy” rating and a $54.00 price objective on the stock. JonesTrading started coverage on shares of Tyra Biosciences in a report on Wednesday, June 17th. They issued a “buy” rating and a $56.00 price target on the stock. Canaccord Genuity Group assumed coverage on shares of Tyra Biosciences in a research report on Monday, April 6th. They set a “buy” rating and a $50.00 price objective for the company. Wolfe Research began coverage on Tyra Biosciences in a report on Tuesday, May 19th. They set a “peer perform” rating for the company. Finally, Bank of America upped their target price on Tyra Biosciences from $37.00 to $42.00 and gave the company a “buy” rating in a research report on Wednesday, June 10th. One research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Tyra Biosciences has an average rating of “Moderate Buy” and an average price target of $47.00.

Tyra Biosciences Stock Performance

TYRA opened at $29.41 on Thursday. The stock has a fifty day moving average of $31.95 and a 200-day moving average of $31.79. The company has a market capitalization of $1.75 billion, a P/E ratio of -13.49 and a beta of 0.76. Tyra Biosciences, Inc. has a fifty-two week low of $9.47 and a fifty-two week high of $40.65.

Tyra Biosciences (NASDAQ:TYRA) last released its quarterly earnings results on Wednesday, May 13th. The company reported ($0.64) EPS for the quarter, missing the consensus estimate of ($0.60) by ($0.04). On average, equities research analysts predict that Tyra Biosciences, Inc. will post -2.68 earnings per share for the current fiscal year.

About Tyra Biosciences

Tyra Biosciences (NASDAQ: TYRA) is a clinical-stage precision oncology company focused on the discovery and development of small-molecule therapies for genetically defined cancers. The company integrates bioinformatics, molecular biology and medicinal chemistry to identify oncogenic drivers and design targeted inhibitors. By leveraging large-scale genomic datasets and functional screening, Tyra Biosciences aims to advance therapies that address patient populations with high unmet medical need.

The company’s pipeline includes multiple programs at various stages of development, each directed against distinct molecular vulnerabilities in cancer cells.